Healthcare - Biotechnology - NASDAQ - US
$ 1.19
2.59 %
$ 12.8 M
Market Cap
-0.44
P/E
CASH FLOW STATEMENT
-21.7 M
OPERATING CASH FLOW
-3 K
INVESTING CASH FLOW
6.2 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
NRx Pharmaceuticals, Inc.
| Net Income | -30.2 M |
| Depreciation & Amortization | 5 K |
| Capital Expenditures | -3 K |
| Stock-Based Compensation | 387 K |
| Change in Working Capital | 5.16 M |
| Others | 5.45 M |
| Free Cash Flow | -21.7 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (30.1) | (39.8) | (93.1) | (51.8) | 0.4 | 66.1 K | (0.1) |
| Depreciation & Amortization | 5 K | 4 K | 2 K | 2 K | 0.859 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | (1.8) | 5.7 | 70.4 K | 0 | 0 |
| Stock Based Compensation | 0.4 | 3.6 | 7.8 | 0.7 | 934 | 0 | 0 |
| Other Operating Activities | 2.9 | (4.3) | 54.3 | 39.6 | (1.3) | (1.6) | (0.1) |
| Change in Working Capital | 5.2 | 0.7 | (4.9) | 3.5 | 4.66 K | 0.5 | 1.33 K |
| Cash From Operations | (21.7) | (39.8) | (37.7) | (2.3) | (0.8) | (0.5) | (0.1) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | 3 K | 10 K | 7 K | 2 K | 3.55 | 0 | 0 |
| Other Items | 0 | 0 | 0 | 0 | 40.2 | (0.6) | (69.0) |
| Cash From Investing Activities | 3 K | 10 K | 7 K | 2 K | 40.2 | (0.6) | (69.0) |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (40.7) | 0 | 70.0 |
| Total Debt Repaid | (3.1) | 9.5 | 0 | 0.6 | 0 | 0.7 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.2 | 22.7 | 26.5 | 50 K | 1.3 | 0 | 0 |
| Cash From Financing Activities | 6.2 | 32.2 | 63.5 | 3.2 | (39.5) | 0.7 | 69.6 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (15.5) | (7.6) | 25.7 | 1.0 | 11.1 K | (0.4) | 0.4 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (21.7) | (39.8) | (37.7) | (2.3) | (0.8) | (0.5) | (0.1) |